array(40) {
  [0]=>
  string(4) "8410"
  ["article_id"]=>
  string(4) "8410"
  [1]=>
  string(76) "Morphic Appoints Acceleron’s Peter Linde as Its Chief Medical Officer"
  ["article_title"]=>
  string(76) "Morphic Appoints Acceleron’s Peter Linde as Its Chief Medical Officer"
  [2]=>
  string(150) "Morphic Therapeutic (NASDAQ: MORF) on Tuesday named Peter Linde as its chief medical officer. Linde was most recently vice president of medical resear"
  ["short_description"]=>
  string(150) "Morphic Therapeutic (NASDAQ: MORF) on Tuesday named Peter Linde as its chief medical officer. Linde was most recently vice president of medical resear"
  [3]=>
  string(370) "Morphic Therapeutic (NASDAQ: MORF) on Tuesday named Peter Linde as its chief medical officer. Linde was most recently vice president of medical research at Acceleron Pharma (NASDAQ: XLRN), where he oversaw the design and execution of clinical trials including late-stage development work on luspatercept, a drug the FDA approved last year for patients with the […]"
  ["description"]=>
  string(370) "Morphic Therapeutic (NASDAQ: MORF) on Tuesday named Peter Linde as its chief medical officer. Linde was most recently vice president of medical research at Acceleron Pharma (NASDAQ: XLRN), where he oversaw the design and execution of clinical trials including late-stage development work on luspatercept, a drug the FDA approved last year for patients with the […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(107) "https://xconomy.com/boston/2020/03/18/morphic-appoints-accelerons-peter-linde-as-its-chief-medical-officer/"
  ["blog_url"]=>
  string(107) "https://xconomy.com/boston/2020/03/18/morphic-appoints-accelerons-peter-linde-as-its-chief-medical-officer/"
  [15]=>
  string(19) "2020-03-18 12:50:23"
  ["add_date"]=>
  string(19) "2020-03-18 12:50:23"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:27"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8824"
  ["article_id"]=>
  string(4) "8824"
  [1]=>
  string(128) "Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome"
  ["article_title"]=>
  string(128) "Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome"
  [2]=>
  string(150) "BOSTON, March 18, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aim"
  ["short_description"]=>
  string(150) "BOSTON, March 18, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aim"
  [3]=>
  string(246) "BOSTON, March 18, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of..."
  ["description"]=>
  string(246) "BOSTON, March 18, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/rhythm-pharmaceuticals-receives-orphan-designation-u-s-fda-setmelanotide-alstr-m-syndrome-18513.html?utm_source=ddc&utm_medium=rss&utm_campaign=Rhythm+Pharmaceuticals+Receives+Orphan+Drug+Designation+from+U.S.+FDA+for+Setmelanotide+for+the+Treatment+of+Alstr%C3%"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/rhythm-pharmaceuticals-receives-orphan-designation-u-s-fda-setmelanotide-alstr-m-syndrome-18513.html?utm_source=ddc&utm_medium=rss&utm_campaign=Rhythm+Pharmaceuticals+Receives+Orphan+Drug+Designation+from+U.S.+FDA+for+Setmelanotide+for+the+Treatment+of+Alstr%C3%"
  [15]=>
  string(19) "2020-03-18 12:04:41"
  ["add_date"]=>
  string(19) "2020-03-18 12:04:41"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:36:45"
  ["create_at"]=>
  string(19) "2020-04-12 16:36:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8402"
  ["article_id"]=>
  string(4) "8402"
  [1]=>
  string(105) "COVID-19: Opportunities for health supplement firms to communicate immune-boosting role of micronutrients"
  ["article_title"]=>
  string(105) "COVID-19: Opportunities for health supplement firms to communicate immune-boosting role of micronutrients"
  [2]=>
  string(150) "A panel of science researchers has put up a list of key findings on the role of micronutrients in supporting the immune system, which firms can tap on"
  ["short_description"]=>
  string(150) "A panel of science researchers has put up a list of key findings on the role of micronutrients in supporting the immune system, which firms can tap on"
  [3]=>
  string(213) "A panel of science researchers has put up a list of key findings on the role of micronutrients in supporting the immune system, which firms can tap on to educate the consumers in light of the coronavirus outbreak."
  ["description"]=>
  string(213) "A panel of science researchers has put up a list of key findings on the role of micronutrients in supporting the immune system, which firms can tap on to educate the consumers in light of the coronavirus outbreak."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "35"
  ["rss_id"]=>
  string(2) "35"
  [14]=>
  string(213) "https://www.nutraingredients-asia.com/Article/2020/03/18/COVID-19-Opportunities-for-health-supplement-firms-to-communicate-immune-boosting-role-of-micronutrients?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(213) "https://www.nutraingredients-asia.com/Article/2020/03/18/COVID-19-Opportunities-for-health-supplement-firms-to-communicate-immune-boosting-role-of-micronutrients?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2020-03-18 09:40:00"
  ["add_date"]=>
  string(19) "2020-03-18 09:40:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:26"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:26"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8563"
  ["article_id"]=>
  string(4) "8563"
  [1]=>
  string(207) "Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch"
  ["article_title"]=>
  string(207) "Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch"
  [2]=>
  string(150) "March 18, 2020 -- Pfizer Inc. (NYSE:PFE) announced today that JADE COMPARE (B7451029) met its co-primary efficacy endpoints. The Phase 3 study evaluat"
  ["short_description"]=>
  string(150) "March 18, 2020 -- Pfizer Inc. (NYSE:PFE) announced today that JADE COMPARE (B7451029) met its co-primary efficacy endpoints. The Phase 3 study evaluat"
  [3]=>
  string(252) "March 18, 2020 -- Pfizer Inc. (NYSE:PFE) announced today that JADE COMPARE (B7451029) met its co-primary efficacy endpoints. The Phase 3 study evaluated the safety and efficacy of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1)..."
  ["description"]=>
  string(252) "March 18, 2020 -- Pfizer Inc. (NYSE:PFE) announced today that JADE COMPARE (B7451029) met its co-primary efficacy endpoints. The Phase 3 study evaluated the safety and efficacy of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1)..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/pfizer-announces-positive-top-line-results-third-phase-3-trial-abrocitinib-moderate-severe-atopic-18492.html?utm_source=ddc&utm_medium=rss&utm_campaign=Pfizer+Announces+Positive+Top-Line+Results+from+Third+Phase+3+Trial+of+Abrocitinib+for+Moderate+to+Severe+Atop"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/pfizer-announces-positive-top-line-results-third-phase-3-trial-abrocitinib-moderate-severe-atopic-18492.html?utm_source=ddc&utm_medium=rss&utm_campaign=Pfizer+Announces+Positive+Top-Line+Results+from+Third+Phase+3+Trial+of+Abrocitinib+for+Moderate+to+Severe+Atop"
  [15]=>
  string(19) "2020-03-18 09:03:42"
  ["add_date"]=>
  string(19) "2020-03-18 09:03:42"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8564"
  ["article_id"]=>
  string(4) "8564"
  [1]=>
  string(159) "Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older"
  ["article_title"]=>
  string(159) "Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older"
  [2]=>
  string(150) "March 18, 2020 -- Pfizer Inc. (NYSE:PFE) today announced top-line results from one of its Phase 3 studies (NCT03760146), which evaluated the safety an"
  ["short_description"]=>
  string(150) "March 18, 2020 -- Pfizer Inc. (NYSE:PFE) today announced top-line results from one of its Phase 3 studies (NCT03760146), which evaluated the safety an"
  [3]=>
  string(249) "March 18, 2020 -- Pfizer Inc. (NYSE:PFE) today announced top-line results from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate in adults 18..."
  ["description"]=>
  string(249) "March 18, 2020 -- Pfizer Inc. (NYSE:PFE) today announced top-line results from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate in adults 18..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/pfizer-announces-top-line-results-phase-3-study-20-valent-pneumococcal-conjugate-vaccine-18493.html?utm_source=ddc&utm_medium=rss&utm_campaign=Pfizer+Announces+Top-Line+Results+from+Phase+3+Study+of+20-Valent+Pneumococcal+Conjugate+Vaccine+in+Pneumococcal+Vaccin"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/pfizer-announces-top-line-results-phase-3-study-20-valent-pneumococcal-conjugate-vaccine-18493.html?utm_source=ddc&utm_medium=rss&utm_campaign=Pfizer+Announces+Top-Line+Results+from+Phase+3+Study+of+20-Valent+Pneumococcal+Conjugate+Vaccine+in+Pneumococcal+Vaccin"
  [15]=>
  string(19) "2020-03-18 09:03:12"
  ["add_date"]=>
  string(19) "2020-03-18 09:03:12"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:05"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8535"
  ["article_id"]=>
  string(4) "8535"
  [1]=>
  string(120) "Janssen Submits Ponesimod New Drug Application to the U.S. FDA for Treatment of Adults with Relapsing Multiple Sclerosis"
  ["article_title"]=>
  string(120) "Janssen Submits Ponesimod New Drug Application to the U.S. FDA for Treatment of Adults with Relapsing Multiple Sclerosis"
  [2]=>
  string(150) "TITUSVILLE, NEW JERSEY, March 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced the submission "
  ["short_description"]=>
  string(150) "TITUSVILLE, NEW JERSEY, March 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced the submission "
  [3]=>
  string(249) "TITUSVILLE, NEW JERSEY, March 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ponesimod for..."
  ["description"]=>
  string(249) "TITUSVILLE, NEW JERSEY, March 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ponesimod for..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(211) "https://www.drugs.com/nda/ponesimod_200318.html?utm_source=ddc&utm_medium=rss&utm_campaign=Janssen+Submits+Ponesimod+New+Drug+Application+to+the+U.S.+FDA+for+Treatment+of+Adults+with+Relapsing+Multiple+Sclerosis"
  ["blog_url"]=>
  string(211) "https://www.drugs.com/nda/ponesimod_200318.html?utm_source=ddc&utm_medium=rss&utm_campaign=Janssen+Submits+Ponesimod+New+Drug+Application+to+the+U.S.+FDA+for+Treatment+of+Adults+with+Relapsing+Multiple+Sclerosis"
  [15]=>
  string(19) "2020-03-18 08:03:04"
  ["add_date"]=>
  string(19) "2020-03-18 08:03:04"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:00"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:00"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8411"
  ["article_id"]=>
  string(4) "8411"
  [1]=>
  string(88) "AbCellera’s Coronavirus “Neutralizing” Antibody Leads Enter Screening"
  ["article_title"]=>
  string(88) "AbCellera’s Coronavirus “Neutralizing” Antibody Leads Enter Screening"
  [2]=>
  string(150) "Vancouver-based biotech AbCellera Biologics has identified more than 500 antibodies that could potentially be turned into medicines to treat the SARS-"
  ["short_description"]=>
  string(150) "Vancouver-based biotech AbCellera Biologics has identified more than 500 antibodies that could potentially be turned into medicines to treat the SARS-"
  [3]=>
  string(397) "Vancouver-based biotech AbCellera Biologics has identified more than 500 antibodies that could potentially be turned into medicines to treat the SARS-CoV-2 novel coronavirus. Now scientists at the National Institutes of Health (NIH), with which the company has been working to prepare medical countermeasures for pandemic outbreaks, are testing the candidates to determine which are most […]"
  ["description"]=>
  string(397) "Vancouver-based biotech AbCellera Biologics has identified more than 500 antibodies that could potentially be turned into medicines to treat the SARS-CoV-2 novel coronavirus. Now scientists at the National Institutes of Health (NIH), with which the company has been working to prepare medical countermeasures for pandemic outbreaks, are testing the candidates to determine which are most […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(107) "https://xconomy.com/national/2020/03/17/abcelleras-coronavirus-neutralizing-antibody-leads-enter-screening/"
  ["blog_url"]=>
  string(107) "https://xconomy.com/national/2020/03/17/abcelleras-coronavirus-neutralizing-antibody-leads-enter-screening/"
  [15]=>
  string(19) "2020-03-18 07:43:29"
  ["add_date"]=>
  string(19) "2020-03-18 07:43:29"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:27"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8337"
  ["article_id"]=>
  string(4) "8337"
  [1]=>
  string(77) "Regeneron Finds Hundreds of COVID-19 Antibodies, Says Trials Could Start Soon"
  ["article_title"]=>
  string(77) "Regeneron Finds Hundreds of COVID-19 Antibodies, Says Trials Could Start Soon"
  [2]=>
  string(153) "&#nl        Regeneron has identified hundreds of coronavirus antibodies for developing treatments for COVID-19 and hopes to start clinical trials by earl"
  ["short_description"]=>
  string(153) "&#nl        Regeneron has identified hundreds of coronavirus antibodies for developing treatments for COVID-19 and hopes to start clinical trials by earl"
  [3]=>
  string(172) "&#nl        Regeneron has identified hundreds of coronavirus antibodies for developing treatments for COVID-19 and hopes to start clinical trials by early summer.&#nl      "
  ["description"]=>
  string(172) "&#nl        Regeneron has identified hundreds of coronavirus antibodies for developing treatments for COVID-19 and hopes to start clinical trials by early summer.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(116) "https://www.fdanews.com/articles/196288-regeneron-finds-hundreds-of-covid-19-antibodies-says-trials-could-start-soon"
  ["blog_url"]=>
  string(116) "https://www.fdanews.com/articles/196288-regeneron-finds-hundreds-of-covid-19-antibodies-says-trials-could-start-soon"
  [15]=>
  string(19) "2020-03-18 06:34:10"
  ["add_date"]=>
  string(19) "2020-03-18 06:34:10"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:54"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:54"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8368"
  ["article_id"]=>
  string(4) "8368"
  [1]=>
  string(50) "COVID-19 coronavirus epidemic has a natural origin"
  ["article_title"]=>
  string(50) "COVID-19 coronavirus epidemic has a natural origin"
  [2]=>
  string(150) "An analysis of public genome sequence data from SARS-CoV-2 and related viruses found no evidence that the virus was made in a laboratory or otherwise "
  ["short_description"]=>
  string(150) "An analysis of public genome sequence data from SARS-CoV-2 and related viruses found no evidence that the virus was made in a laboratory or otherwise "
  [3]=>
  string(162) "An analysis of public genome sequence data from SARS-CoV-2 and related viruses found no evidence that the virus was made in a laboratory or otherwise engineered. "
  ["description"]=>
  string(162) "An analysis of public genome sequence data from SARS-CoV-2 and related viruses found no evidence that the virus was made in a laboratory or otherwise engineered. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200317175442.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200317175442.htm"
  [15]=>
  string(19) "2020-03-18 05:54:42"
  ["add_date"]=>
  string(19) "2020-03-18 05:54:42"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:16"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8428"
  ["article_id"]=>
  string(4) "8428"
  [1]=>
  string(71) "The Biggest Threat to Medical Device Revenue Growth During the Pandemic"
  ["article_title"]=>
  string(71) "The Biggest Threat to Medical Device Revenue Growth During the Pandemic"
  [2]=>
  string(165) "&#nlIn a new report, Needham & Co.'s Mike Matson says he doesn't expect an economic slowdown to weigh directly on medtech growth, but that doesn't me"
  ["short_description"]=>
  string(165) "&#nlIn a new report, Needham & Co.'s Mike Matson says he doesn't expect an economic slowdown to weigh directly on medtech growth, but that doesn't me"
  [3]=>
  string(3068) "&#nl
In a new report, Needham & Co.'s Mike Matson says he doesn't expect an economic slowdown to weigh directly on medtech growth, but that doesn't mean the industry will be unaffected by the coronavirus (COVID-19) pandemic.
&#nl
"We think that the biggest threat to medtech revenue growth is a decline in elective procedures," the analyst said, adding that this trend is driven by hospitals cutting back on or stopping elective procedures as they prepare for and focus on COVID-19 patients, and by patients deferring elective procedures due to fears of exposure to the virus.
&#nl
Both factors have already caused large declines in procedures in both China and Italy, and some U.S. cities and states (such as New York City and Massachusetts) have ordered hospitals to stop elective procedures, Matson noted.
&#nl
As MD+DI previously reported, Boston Scientific said in February the virus is expected to lower first-quarter revenue by $10 million to $40 million, and that estimate was based solely on the impact from fewer procedures in China. Also in February, Medtronic acknowledged that slower procedure volume in China would have a negative impact on the company's fiscal fourth-quarter financial results, but CEO Omar Ishrak stopped short of putting any numbers around the issue at that time, given the fluidity of the situation.
&#nl
Needham & Co. conducted what Matson calls a "stress test" consisting of three scenarios (bad, worse, worst) to evaluate the impact of the virus on revenue and earnings per share (EPS) growth reductions in the first three quarters of 2020. His analysis assumes that the first-quarter impact is mostly driven by COVID-19 in China and Italy while the other two quarters' impact is mostly driven by the virus in the United States and the rest of Europe. He says he expects the COVID-19 revenue growth headwinds to peak in the second quarter at 10% in the "bad" case scenario, "30%" in the "worse" case scenario, and 50% in the "worst" case scenario.
&#nl
Needham & Co.'s scenario analysis results in an average 4% to 18% reduction to estimated 2020 revenue and an average 9% to 32% reduction to estimated 2020 EPS for the medical device companies that the firm covers.
&#nl
Small and mid-sized companies are likely to see a bigger hit to EPS than large companies, according to the report. For all three scenarios, the analyst said he expects Stryker, Hologic, and Masimo to see the smallest impacts to EPS. On the other end of the spectrum, Invacare, Inogen, and Hill-Rom could see the largest impacts to EPS, according to Matson's report.
"
  ["description"]=>
  string(3068) "&#nl
In a new report, Needham & Co.'s Mike Matson says he doesn't expect an economic slowdown to weigh directly on medtech growth, but that doesn't mean the industry will be unaffected by the coronavirus (COVID-19) pandemic.
&#nl
"We think that the biggest threat to medtech revenue growth is a decline in elective procedures," the analyst said, adding that this trend is driven by hospitals cutting back on or stopping elective procedures as they prepare for and focus on COVID-19 patients, and by patients deferring elective procedures due to fears of exposure to the virus.
&#nl
Both factors have already caused large declines in procedures in both China and Italy, and some U.S. cities and states (such as New York City and Massachusetts) have ordered hospitals to stop elective procedures, Matson noted.
&#nl
As MD+DI previously reported, Boston Scientific said in February the virus is expected to lower first-quarter revenue by $10 million to $40 million, and that estimate was based solely on the impact from fewer procedures in China. Also in February, Medtronic acknowledged that slower procedure volume in China would have a negative impact on the company's fiscal fourth-quarter financial results, but CEO Omar Ishrak stopped short of putting any numbers around the issue at that time, given the fluidity of the situation.
&#nl
Needham & Co. conducted what Matson calls a "stress test" consisting of three scenarios (bad, worse, worst) to evaluate the impact of the virus on revenue and earnings per share (EPS) growth reductions in the first three quarters of 2020. His analysis assumes that the first-quarter impact is mostly driven by COVID-19 in China and Italy while the other two quarters' impact is mostly driven by the virus in the United States and the rest of Europe. He says he expects the COVID-19 revenue growth headwinds to peak in the second quarter at 10% in the "bad" case scenario, "30%" in the "worse" case scenario, and 50% in the "worst" case scenario.
&#nl
Needham & Co.'s scenario analysis results in an average 4% to 18% reduction to estimated 2020 revenue and an average 9% to 32% reduction to estimated 2020 EPS for the medical device companies that the firm covers.
&#nl
Small and mid-sized companies are likely to see a bigger hit to EPS than large companies, according to the report. For all three scenarios, the analyst said he expects Stryker, Hologic, and Masimo to see the smallest impacts to EPS. On the other end of the spectrum, Invacare, Inogen, and Hill-Rom could see the largest impacts to EPS, according to Matson's report.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(87) "https://www.mddionline.com/biggest-threat-medical-device-revenue-growth-during-pandemic"
  ["blog_url"]=>
  string(87) "https://www.mddionline.com/biggest-threat-medical-device-revenue-growth-during-pandemic"
  [15]=>
  string(19) "2020-03-18 04:45:46"
  ["add_date"]=>
  string(19) "2020-03-18 04:45:46"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:33"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8412"
  ["article_id"]=>
  string(4) "8412"
  [1]=>
  string(72) "Qiagen Juices RNA Extraction Kit Capacity to Feed Coronavirus Test Needs"
  ["article_title"]=>
  string(72) "Qiagen Juices RNA Extraction Kit Capacity to Feed Coronavirus Test Needs"
  [2]=>
  string(150) "Dutch molecular diagnostics company Qiagen said Tuesday it would “dramatically” ramp up production of the components needed for the RNA ex"
  ["short_description"]=>
  string(150) "Dutch molecular diagnostics company Qiagen said Tuesday it would “dramatically” ramp up production of the components needed for the RNA ex"
  [3]=>
  string(361) "Dutch molecular diagnostics company Qiagen said Tuesday it would “dramatically” ramp up production of the components needed for the RNA extraction kits used to detect the novel coronavirus in a patient sample. Isolating genetic material from a biological sample is a key step in the testing process, which has not been widespread in the US […]"
  ["description"]=>
  string(361) "Dutch molecular diagnostics company Qiagen said Tuesday it would “dramatically” ramp up production of the components needed for the RNA extraction kits used to detect the novel coronavirus in a patient sample. Isolating genetic material from a biological sample is a key step in the testing process, which has not been widespread in the US […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(113) "https://xconomy.com/national/2020/03/17/qiagen-juices-rna-extraction-kit-capacity-to-feed-coronavirus-test-needs/"
  ["blog_url"]=>
  string(113) "https://xconomy.com/national/2020/03/17/qiagen-juices-rna-extraction-kit-capacity-to-feed-coronavirus-test-needs/"
  [15]=>
  string(19) "2020-03-18 04:45:26"
  ["add_date"]=>
  string(19) "2020-03-18 04:45:26"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:27"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8429"
  ["article_id"]=>
  string(4) "8429"
  [1]=>
  string(68) "Head Mounted Displays Could Help People Overcome Glaucoma Challenges"
  ["article_title"]=>
  string(68) "Head Mounted Displays Could Help People Overcome Glaucoma Challenges"
  [2]=>
  string(153) "&#nlA recent study from the Crabb Lab, at City, University of London shows how commercially available head-mounted displays (HMD) can be used to simulate"
  ["short_description"]=>
  string(153) "&#nlA recent study from the Crabb Lab, at City, University of London shows how commercially available head-mounted displays (HMD) can be used to simulate"
  [3]=>
  string(2248) "&#nl
A recent study from the Crabb Lab, at City, University of London shows how commercially available head-mounted displays (HMD) can be used to simulate the day-to-day challenges faced by people with glaucoma.
&#nl
Twenty-two volunteers who did not have glaucoma took part in the study and wore an HMD while performing various tasks in either virtual or augmented reality. The study is published in the online journal, npj Digital Medicine. In the virtual reality task, participants were placed in a simulation of a typical, 'cluttered' house. Moving their eyes and head allowed them to look around it in order to find a mobile phone hidden somewhere in the house.
&#nl
In the augmented reality task, participants navigated a real-life, human-sized 'mouse maze', which they viewed through cameras in the front of the HMD.
&#nl
Sensors in the HMD tracked the position of the participant's eyes, allowing the software to generate a blurred area of vision, known as a 'scotoma', that obstructed the same portion of their visual field, wherever they looked. The scotoma was created using medical data from a real glaucoma patient, and either restricted vision in the upper part of the participant's visual field, or in the bottom part. In 'control' trials the scotoma was absent.
&#nl
Similar to real glaucoma patients, participants were slower to perform the tasks when the simulated impairment was present and made more head and eye movements too. They likewise found the tasks particularly difficult when the vision loss obstructed the bottom part of their visual field. The results also showed how some people were better able to cope than others with an identical impairment.
&#nl
The software the authors created to simulate the visual impairment (OpenVisSim) has been shared online for others to freely use and develop. It is compatible with most commercially available HMDs and smartphones and supports a range of visual effects, designed to simulate the different symptoms associated with a range of eye diseases.
"
  ["description"]=>
  string(2248) "&#nl
A recent study from the Crabb Lab, at City, University of London shows how commercially available head-mounted displays (HMD) can be used to simulate the day-to-day challenges faced by people with glaucoma.
&#nl
Twenty-two volunteers who did not have glaucoma took part in the study and wore an HMD while performing various tasks in either virtual or augmented reality. The study is published in the online journal, npj Digital Medicine. In the virtual reality task, participants were placed in a simulation of a typical, 'cluttered' house. Moving their eyes and head allowed them to look around it in order to find a mobile phone hidden somewhere in the house.
&#nl
In the augmented reality task, participants navigated a real-life, human-sized 'mouse maze', which they viewed through cameras in the front of the HMD.
&#nl
Sensors in the HMD tracked the position of the participant's eyes, allowing the software to generate a blurred area of vision, known as a 'scotoma', that obstructed the same portion of their visual field, wherever they looked. The scotoma was created using medical data from a real glaucoma patient, and either restricted vision in the upper part of the participant's visual field, or in the bottom part. In 'control' trials the scotoma was absent.
&#nl
Similar to real glaucoma patients, participants were slower to perform the tasks when the simulated impairment was present and made more head and eye movements too. They likewise found the tasks particularly difficult when the vision loss obstructed the bottom part of their visual field. The results also showed how some people were better able to cope than others with an identical impairment.
&#nl
The software the authors created to simulate the visual impairment (OpenVisSim) has been shared online for others to freely use and develop. It is compatible with most commercially available HMDs and smartphones and supports a range of visual effects, designed to simulate the different symptoms associated with a range of eye diseases.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(95) "https://www.mddionline.com/head-mounted-displays-could-help-people-overcome-glaucoma-challenges"
  ["blog_url"]=>
  string(95) "https://www.mddionline.com/head-mounted-displays-could-help-people-overcome-glaucoma-challenges"
  [15]=>
  string(19) "2020-03-18 04:26:18"
  ["add_date"]=>
  string(19) "2020-03-18 04:26:18"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:33"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}